Targeting Early Dementia: Using Lipid Cubic-Phase Nanocarriers to Cross the Blood-Brain Barrier
Keyword(s):
Class B
◽
Over past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer's disease pathology has been observed. Numerous published studies indicate that preservation of healthy cerebrovascular endothelium can be an important therapeutic target. By incorporating appropriate drug(s) into biomimetic (lipid cubic-phase) nanocarriers, one obtains a multitasking combination therapeutic which targets certain cell-surface scavenger receptors, mainly class B type 1 (i.e., SR-BI), and crosses the blood-brain barrier. This targeting allows for various Alzheimer’s-related cell types to be simultaneously searched out for localized drug treatment in vivo.
2009 ◽
Vol 29
(12)
◽
pp. 1879-1884
◽
Keyword(s):
2021 ◽
Keyword(s):
2021 ◽
pp. 0271678X2110395
Keyword(s):
1996 ◽
Vol 22
(2)
◽
pp. 118-128
◽
Keyword(s):
Keyword(s):